The latest price target for Integra Lifesciences (NASDAQ:IART) was reported by Citigroup on November 5, 2024. The analyst firm set a price target for $22.00 expecting IART to fall to within 12 months (a possible -4.26% downside). 27 analyst firms have reported ratings in the last year.

The latest analyst rating for Integra Lifesciences (NASDAQ:IART) was provided by Citigroup, and Integra Lifesciences maintained their sell rating.

The last upgrade for Integra Lifesciences Holdings Corp happened on October 7, 2024 when BTIG raised their price target to N/A. BTIG previously had a sell for Integra Lifesciences Holdings Corp.

The last downgrade for Integra Lifesciences Holdings Corp happened on July 30, 2024 when Citigroup changed their price target from $30 to $23 for Integra Lifesciences Holdings Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Integra Lifesciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Integra Lifesciences was filed on November 5, 2024 so you should expect the next rating to be made available sometime around November 5, 2025.

While ratings are subjective and will change, the latest Integra Lifesciences (IART) rating was a maintained with a price target of $16.00 to $22.00. The current price Integra Lifesciences (IART) is trading at is $22.98, which is out of the analyst’s predicted range.